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anBACKGROUND Prior studies of catheter-based renal artery denervation have not systematically performed ambulatory
blood pressure monitoring (ABPM) to assess the efﬁcacy of the procedure.
OBJECTIVES SYMPLICITY HTN-3 (Renal Denervation in Patients With Uncontrolled Hypertension) was a prospective,
blinded, randomized, sham-controlled trial. The current analysis details the effect of renal denervation or a sham
procedure on ABPM measurements 6 months post-randomization.
METHODS Patientswith resistant hypertensionwere randomized2:1 to renal denervation or shamcontrol. Patientswere on a
stable antihypertensive regimen including maximally tolerated doses of at least 3 drugs including a diuretic before randomi-
zation. The powered secondary efﬁcacy endpoint was a change in mean 24-h ambulatory systolic blood pressure (SBP). Non-
dipper to dipper (nighttime blood pressure [BP] 10% to 20% lower than daytime BP) conversion was calculated at 6 months.
RESULTS The 24-h ambulatory SBP changed 6.8  15.1 mm Hg in the denervation group and 4.8  17.3 mm Hg in
the sham group: difference of 2.0 mm Hg (95% conﬁdence interval [CI]: 5.0 to 1.1; p ¼ 0.98 with a 2 mm Hg
superiority margin). The daytime ambulatory SBP change difference between groups was 1.1 (95% CI: 4.3 to 2.2;
p ¼ 0.52). The nocturnal ambulatory SBP change difference between groups was 3.3 (95 CI: 6.7 to 0.1; p ¼ 0.06).
The percent of nondippers converted to dippers was 21.2% in the denervation group and 15.0% in the sham group
(95% CI: 3.8% to 16.2%; p ¼ 0.30). Change in 24-h heart rate was 1.4  7.4 in the denervation group and 1.3  7.3
in the sham group; (95% CI: 1.5 to 1.4; p ¼ 0.94).
CONCLUSIONS This trial did not demonstrate a beneﬁt of renal artery denervation on reduction in ambulatory BP
in either the 24-h or day and night periods compared with sham (Renal Denervation in Patients With Uncontrolled
Hypertension [SYMPLICITY HTN-3]; NCT01418261) (J Am Coll Cardiol 2014;64:1071–8) © 2014 by the American
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ABPM = ambulatory blood
pressure monitoring
DBP = diastolic blood pressure
SBP = systolic blood pressure
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1072A mbulatory blood pressure moni-toring (ABPM) is recommended forinitial evaluation of all persons with
newly diagnosed hypertension and for evalu-
ation of antihypertensive drug efﬁcacy in
blood pressure (BP) trials (1,2). Its importance
is exempliﬁed by positive outcomes on ABPMin a randomized trial in which ofﬁce readings were
not different (3). Early studies of renal denervation
in participants with resistant hypertension did
not assess ABPM in all participants studied (4,5).
SYMPLICITY HTN-3 (Renal Denervation in Patients
With Uncontrolled Hypertension) was a prospective,
blinded, randomized, sham-controlled trial. In this
trial, ABPM was an inclusion criterion, and all partic-
ipants were evaluated at baseline and at 6 months;
the change in ambulatory systolic blood pressure
(SBP) from baseline to 6 months was a pre-speciﬁed,
powered secondary endpoint (6,7). The primary re-
sults of the trial demonstrated the safety of the renal
denervation procedure but failed to show a greater
reduction in ofﬁce or ambulatory SBP compared
with the sham procedure at 6 months (7). This paper
presents the detailed 24-h ABPM results of SYMPLIC-
ITY HTN-3.SEE PAGE 1088METHODS
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STUDY POPULATION. Patients on a stable antihy-
pertensive drug regimen including maximally toler-
ated doses of $3 antihypertensive medications of
complementary classes, including an appropriately
dosed diuretic, were required to have seated ofﬁce
SBP $160 mm Hg (using the average of 3 measure-
ments) at their ﬁrst screening visit. For the 2 weeks
before the second screening visit, patients recorded
their home BP and kept a diary recording their
adherence to medical therapy. Antihypertensive
medication changes were not allowed during this
2-week period. At the second screening visit, the
ofﬁce SBP $160 mm Hg was conﬁrmed, adherence
with medications was documented, and 24-h ABPM
was performed to ensure an ambulatory SBP $135
mm Hg. All ABPMs were performed with the Space
Labs 24 Ambulatory Blood Pressure Monitoring Sys-
tem (Space Labs Medical, Issaquah, Washington).
Patients were instructed to place the cuff on the same
arm as used for ofﬁce BP measurements, and the
importance of leaving the cuff in place was stressed.
The ABPM parameters were preset to measure BP
every 30 min during the day (7:00 AM to 9:59 PM) and
for every 30 min at night (10:00 PM to 6:59 AM). Pa-
tients were instructed to engage in their normal daily
activities and to hold their arm still by their side to
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TABLE 1 Baseline Characteristics of the Study Population*
Renal Denervation
Group
(N ¼ 364)
Sham Procedure
Group
(N ¼ 171)
Age, yrs 57.9  10.4 56.2  11.2
Male 215 (59.1) 110 (64.3)
BMI, kg/m2 34.2  6.5 33.9  6.4
Race
Black 90 (24.8) 50 (29.2)
White 265 (73.0) 119 (69.6)
Other 8 (2.3) 2 (1.2)
Medical history
Renal insufﬁciency (eGFR <60 ml/min/1.73 m2) 34 (9.3) 17 (9.9)
Coronary artery disease 101 (27.7) 43 (25.1)
Diabetes, type 2 171 (47.0) 70 (40.9)
24-h heart rate, beats/min 71.0  13.0 72.4  12.3
Ambulatory blood pressure
24-h systolic 159.1  13.2 159.5  15.3
24-h diastolic 88.0  14.0 90.9  14.4
Daytime systolic 163.0  13.4 164.2  15.0
Daytime diastolic 91.3  14.5 94.78  15.0
Nighttime systolic 152.5  16.3 151.4  18.7
Nighttime diastolic 82.5  14.5 84.3  15.1
Dipper status
Extreme dipper 12/360 (3.3) 9/167 (5.4)
Dipper 96/360 (26.7) 52/167 (31.1)
Nondipper 185/360 (51.4) 83/167 (49.7)
Reverse dipper 67/360 (18.6) 23/167 (13.8)
Conversion of nondipper to dipper at 6 months 35/165 (21.2) 12/80 (15.0)
Number of BP lowering medications 5.1  1.4 5.2  1.4
ACE inhibitors 179 (49.2) 71 (41.5)
% at max tolerated dose 167 (45.9) 64 (37.4)
Angiotensin receptor blockers 182 (50.0) 91 (53.2)
% at max tolerated dose 180 (49.5) 88 (51.5)
Aldosterone antagonists 82 (22.5) 49 (28.7)
Alpha-adrenergic blockers 40 (11.0) 23 (13.5)
Beta-blockers 310 (85.2) 147 (86.0)
Calcium channel blockers 254 (69.8) 125 (73.1)
% at max tolerated dose 208 (57.1) 109 (63.7)
Centrally acting sympatholytics 179 (49.2) 75 (43.9)
Diuretics 363 (99.7) 171 (100)
% at max tolerated dose 351 (96.4) 167 (97.7)
Direct renin inhibitors 26 (7.1) 12 (7.0)
Direct-acting vasodilators 134 (36.8) 77 (45.0)
Values are mean  SD or n (%). *All differences in characteristics between groups are nonsigniﬁcant.
ACE ¼ angiotensin-converting enzyme; BMI ¼ body mass index; BP ¼ blood pressure; eGFR ¼ estimated
glomerular ﬁltration rate.
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1073All patients kept a diary that documented time to bed
and time waking up, medications taken, and any
other events of signiﬁcance. On return of the ABPM
machine, the patients’ diaries were collected, and the
ABPM data were downloaded to a computer. A 24-h
ABPM was considered adequate if the number of
successful daytime readings captured was at least 21
and the number of successful nighttime readings
captured was at least 12. Only ABPMs with the pre-
speciﬁed number of readings per protocol were in-
cluded in the analysis.
Additional clinical exclusion criteria included known
secondary causes of hypertension or more than 1 hospi-
talization for a hypertensive emergency in the past year.
Anatomic exclusion criteria included >50% renal artery
stenosis, renal artery aneurysm, prior renal artery inter-
vention, multiple renal arteries, renal artery diameter
<4 mm, or treatable segment <20 mm in length.
After undergoing a renal angiogram and an
assessment of anatomy, patients were randomized to
either renal artery denervation or the sham control
group in a 2:1 ratio. Patients were followed for
6 months, at which time the primary and pre-
speciﬁed powered ambulatory SBP secondary end-
points were assessed. Patients in the control group
were then allowed to cross over to receive renal
denervation treatment, if they still met the inclusion
criteria for the study.
STUDY PROCEDURE. The renal denervation proce-
dure used radiofrequency energy delivered by the
Symplicity Renal Denervation System (Medtronic,
Santa Rosa, California) to ablate the nerves within the
main renal arteries. Patients were blinded to whether
they received renal artery denervation or only renal
angiography (sham). Assessors of BP and study per-
sonnel also were blinded to the treatment received by
patients. Details of the blinding procedure and con-
ﬁrmation of adequate blinding have been provided
previously (7). Antihypertensive medication changes
were not allowed during the 6-month follow-up
period unless clinically required.
ENDPOINTS. The primary efﬁcacy endpoint was a
comparison of ofﬁce SBP change from baseline to
6 months in the renal denervation group compared
with the SBP change from baseline to 6 months in
the sham control group and required a superiority
margin of 5 mm Hg for success. The secondary efﬁ-
cacy endpoint was the change in mean 24-h ambu-
latory SBP at 6 months. In addition to 24-h ABPM,
daytime and nighttime ambulatory BP differences
from baseline to 6 months, as well as differences in
the change between the 2 groups, were assessed.
ABPM differences in BP and heart rate variabilityalso were assessed at baseline and at 6 months for
both groups.
The proportion of patients who were extreme
dippers (decline of >20% in night to day BP), dippers
(10% to 20% decline in night to day BP), nondippers
(<10% decline in BP at night), and reverse dippers
(night BP greater than day BP) were calculated at each
follow-up visit.
For the current analysis, patients in each group
were further categorized according to tertiles of
Denervation
Number of patients Difference
(95% Cl) mmHg p value
Interaction
p valueSham
325
157
168
192
133
76
248
87
238
73
252
65
260
230
95
121
204
All patients
Diabetes mellitus
     Yes
     No
Sex 
     Male
     Female
African American
     Yes
     No
BMI
     <30 kg/m2
     ≥30 kg/m2
On AA at baseline
     Yes
     No
eGFR
     <60 mL/min/1.73 m2
     ≥60 mL/min/1.73 m2
Age
     <65 y
     ≥65 y
Any medication change
     Yes
     No 
159 
62
97
99
60
47
112
42
116
46
113
35
124
119
40
66
93
0.979
0.975
0.113
0.243
0.515
0.782
0.158
0.663
0.269
0.127
0.574
0.501
0.324
0.245
0.480
0.195
0.551
-1.96 (-4.97 to 1.06)
0.08 (-4.55 to 4.71)
-3.24 (-7.26 to 0.77)
-2.01 (-5.41 to 1.38)
-1.87 (-7.52 to 3.79)
-0.88 (-7.19 to 5.42)
-2.48 (-5.93 to 0.97)
-1.14 (-6.30 to 4.02)
-2.19 (-5.88 to 1.49)
-5.70 (-12.46 to 1.07)
-0.95 (-4.27 to 2.37)
-2.50 (-8.90 to 3.90)
-1.71 (-5.13 to 1.70)
-2.24 (-6.01 to 1.54)
-1.62 (-6.16 to 2.91)
-3.58 (-9.01 to 1.85)
-1.14 (-4.63 to 2.34)
0.287
0.963
0.643
0.762
0.171
0.834
0.860
0.434
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CENTRAL ILLUSTRATION Change in Ambulatory Systolic Blood Pressure for All
Patients and Pre-speciﬁed Subgroups in the SYMPLICITY HTN-3 Trial
(Top) The mean 24-h ambulatory systolic and diastolic blood pressure at baseline and at 6
months are shown from both study groups. (Bottom) The change in ambulatory systolic
blood pressure at 6 months is displayed for pre-speciﬁed subgroups. Squares denote
blood pressure changes, and horizontal lines represent 95% conﬁdence intervals. BMI ¼
body mass index; BP ¼ blood pressure; CI ¼ conﬁdence interval; DBP ¼ diastolic blood
pressure; eGFR ¼ estimated glomerular ﬁltration rate; SBP ¼ systolic blood pressure;
SYMPLICITY HTN-3 ¼ Renal Denervation in Patients With Uncontrolled Hypertension.
Bakris et al. J A C C V O L . 6 4 , N O . 1 1 , 2 0 1 4
Renal Denervation and 24-h Ambulatory BP S E P T E M B E R 1 6 , 2 0 1 4 : 1 0 7 1 – 8
1074baseline ambulatory SBP. Baseline and 6-month
ABPMmeasurements were determined for each group.
The primary safety endpoint has been previously
described and reported (7). Treated patients will
be followed biannually, and non-crossover control
patients will be followed annually through 5 years
post-randomization.
STATISTICAL ANALYSES. The analyses were per-
formed based on the intent-to-treat principle. The
data were collected and analyzed by the sponsor
(Medtronic, Minneapolis, Minnesota) and indepen-
dently validated by Harvard Clinical Research Insti-
tute (Boston, Massachusetts). Means and standard
deviations of continuous variables were presented by
treatment group. Variability of ambulatory BP in eachvisit was deﬁned as the standard deviation (SD) or
coefﬁcient of variation (%, 100  SD / mean). Between
group differences were compared using conﬁdence
intervals (CI) and evaluated using unpaired Student
t tests. Within group differences from baseline to
follow-up were evaluated using paired Student
t tests. For categorical variables, the treatment group
presented the counts and percentages. They were
tested using the exact test for binary variables and
chi-square test for multi-level categorical variables.
All subgroups shown were pre-speciﬁed.
Differences within and between groups of early
morning slope analysis also were calculated. Baseline
ambulatory SBP was plotted against early morning
time (3 AM to 8 AM), and the slopes of the regression
lines were calculated for each group at baseline and at
6 months. The changes in slopes from baseline to
6 months for each group were compared using anal-
ysis of covariance.
RESULTS
All randomized patients (n ¼ 535) had an ABPM placed
as part of the inclusion criteria for the study (7).
No signiﬁcant differences in baseline characteristics
were noted between the 2 groups with the exception
of 24-h and daytime diastolic blood pressure (DBP),
which was greater in the sham control group
(Table 1). Patients were taking an average of 5 anti-
hypertensive medications, and on average 4 medi-
cations were at maximally tolerated doses (7).
Antihypertensive medication use remained similar in
both groups at 6-month follow-up.
The primary efﬁcacy endpoint was the mean
change in ofﬁce SBP from baseline to 6 months in the
denervation group, as compared with the mean
change in the sham control group, with a superiority
margin of 5 mm Hg. This endpoint was not different
from the sham control group (7). The powered sec-
ondary efﬁcacy endpoint was the change in mean
24-h ambulatory SBP at 6 months between groups
with a superiority margin of 2 mm Hg. This endpoint
was also not different between groups (6.75 
15.11 mm Hg in the denervation group and 4.79 
17.25 mm Hg in the sham group, for a difference be-
tween groups of 1.96 mm Hg [95% CI: 4.97 to 1.06;
p value with a 2 mm Hg superiority margin ¼ 0.98])
(Central Illustration). The ambulatory DBPs were
consistent with the trends in ambulatory SBPs
(Central Illustration). The mean daytime and night-
time BPs in both groups also were not different be-
tween groups at 6 months (Figures 1 and 2).
The greatest reduction from baseline in mean 24-h
SBP occurred in patients who were in the highest
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Denervation Sham Denervation Sham
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Δ=-1.1 (95% CI, -4.3 to 2.2)
p=0.52
p<0.001
Δ=-7.2 (95% CI, -8.9 to -5.5)
p<0.001
Δ=-6.1 (95% CI, -8.9 to -3.3)
p=0.62
Δ=-0.5 (95% CI, -2.5 to 1.5)
p<0.001
Δ=-4.4 (95% CI, -5.4 to 3.4)
p<0.001
Δ=-3.9 (95% CI, -5.6 to -2.2)
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(N=361) (N=334) (N=168) (N=163) (N=360) (N=334) (N=167) (N=163)
FIGURE 1 Daytime Blood Pressure Readings
Depicted here are the mean ambulatory daytime systolic and diastolic blood pressure at
baseline and at 6 months. BP ¼ blood pressure; CI ¼ conﬁdence interval; DBP ¼ diastolic
blood pressure; SBP ¼ systolic blood pressure.
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FIGURE 2 Nighttime Blood Pressure Readings
Depicted here are the mean ambulatory nighttime systolic and diastolic blood pressure at
baseline and at 6 months. Abbreviations as in Figure 1.
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1075baseline ambulatory SBP tertile (Figure 3). There was
no signiﬁcant change from baseline for the lowest
tertile group and no difference in any of the ABPM
changes between the denervation and sham groups.
Mean 24-h heart rates were similar at baseline and at
6 months in the 2 lower tertiles. Details of 24-h,
daytime, nighttime, and heart rate measures are
reported in Online Table 1.
The proportion of patients who converted from
nondipper to dipper at 6 months post-randomization
was 21.2% in the denervation group and 15.0% in the
sham control group (difference, 6.2%; 95% CI: 3.8 to
16.2%). Early morning (3 AM to 8 AM) SBP increases were
not signiﬁcant for either group, with a slope change
of 0.05 at 6 months for the denervation group
(p ¼ 0.90) and 0.52 in the sham group (p ¼ 0.35).
No change was noted in 24-h, daytime, or night-
time BP or heart rate variability assessed by ABPM
between or within groups (Table 2, Online Table 2).
The differences in ambulatory SBP from baseline to
6 months in various subgroups of participants are
shown in the Central Illustration. The absolute mag-
nitudes of difference were small (<6 mm Hg) and not
signiﬁcant in any of the pre-speciﬁed subgroups. No
signiﬁcant differences were noted between groups as
a function of baseline ambulatory SBP. There was no
signiﬁcant difference in 24-h heart rate between
baseline and 6 months 1.36  7.41 for denervation
and 1.30  7.25 for sham control (95% CI: 1.45 to
1.35; p ¼ 0.94).
The primary safety endpoint and other safety
events have been described previously (7). Few major
adverse events occurred in the trial: 1 (0.6%) in
the sham control arm and 5 (1.4%) in the treatment
arm, for a difference of 0.8% (95% CI: 0.9%, 2.5%;
p ¼ 0.67).
DISCUSSION
This randomized, sham-controlled, blinded trial
failed to show a beneﬁt of renal artery denerva-
tion on the powered secondary endpoint of 24-h
ambulatory SBP. Daytime and nighttime ABPM and
heart rate change were also not different between
the denervation and sham control groups. Earlier
unblinded trials of renal denervation demonstra-
ted signiﬁcant reductions in ABPM measurements
6 months post-denervation that were similar in
magnitude to the current trial, but without the
beneﬁt of a blinded control (8,9). Previous renal
denervation studies reported smaller decreases in
24-h and daytime ABPM than ofﬁce BP; this ﬁnding is
consistent with our observations (8,9). This BP dif-
ference between ofﬁce and ambulatory settings waspredicted by a meta-analysis of antihypertensive
drug and renal denervation trials that noted that
differences in ofﬁce and ambulatory BP reductions
disappear in double-blind placebo controlled drug
trials (10,11).
ABPM has the advantage of less bias compared
with ofﬁce readings and provides a complete picture
of BP throughout the day. This concept is further
supported by this trial because disappearance of
the difference between ofﬁce and ABPM effect in a
double-blind, placebo-controlled trial suggests that
the placebo effect is stronger for ofﬁce than ABPM
visits. ABPM is generally believed to be less
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FIGURE 3 Changes in 24-h Ambulatory Systolic Blood Pressure
Depicted here is the change in 24-h ambulatory systolic blood pressure by tertiles of
baseline ambulatory 24-h systolic blood pressure. RDN ¼ renal denervation; other
abbreviations as in Table 1.
TABLE 2 Analysis of Ambulatory Blood Pressure and Heart Rate Variability
Renal Denervation
Group
(N ¼ 364)
Sham Procedure
Group
(N ¼ 171)
Difference
[95% CI]
24-h ABPM
Baseline, mm Hg 159.1  13.2 159.5  15.3 0.39 [3.10, 2.31]
6 month, mm Hg 151.8  16.0 153.9  19.1 2.05 [5.48, 1.38]
ABPM variability
SBP
24-h SD, baseline 16.1  4.7 16.0  4.6 0.08 [0.78, 0.95]
24-h SD, 6 months 15.5  4.0 15.6  4.5 0.07 [0.90, 0.75]
24-h CV%, baseline 10.2  3.1 10.2  3.2 0.01 [0.56, 0.59]
24-h CV%, 6 months 10.3  2.7 10.3  3.1 0.04 [0.51, 0.60]
DBP
24-h SD, baseline 11.3  3.0 11.3  3.4 0.05 [0.64, 0.55]
24-h SD, 6 months 11.3  3.0 11.3  3.4 0.05 [0.64, 0.55]
24-h CV%, baseline 13.2  3.7 13.2  3.8 0.02 [0.67, 0.70]
24-h CV%, 6 months 13.7  3.5 13.1  3.9 0.56 [0.12, 1.24]
24-h heart rate
Baseline 71.0  13.0 72.4  12.3 1.41 [3.77, 0.94]
6 months 69.4  12.5 71.0  12.6 1.55 [3.90, 0.81]
Heart rate variability
24-h SD, baseline 8.2  4.2 9.1  4.0 0.85 [1.61, 0.09]
24-h SD, 6 months 8.0  3.7 8.4  3.2 0.47 [1.11, 0.16]
24-h CV%, baseline 11.5  5.1 12.6  5.3 1.07 [2.01, 0.12]
24-h CV%, 6 months 11.4  4.9 12.0  4.4 0.55 [1.44, 0.34]
Values are mean  SD.
ABPM ¼ ambulatory blood pressure monitoring; CI ¼ conﬁdence interval; CV ¼ coefﬁcient of variation;
DBP ¼ diastolic blood pressure; SBP ¼ systolic blood pressure.
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1076vulnerable to placebo-like effects because it is
assessed in a patient’s daily life (12). Given that area
under the curve of the 24-h ABPM is more accurate
than ofﬁce readings taken at ﬁxed times, differences
in BP may be detected by ABPM when ofﬁce read-
ings fail to show differences (3). In the current
trial, no such differences were noted, although a
trend was noted for a greater nighttime BP reduc-
tion in the denervation group compared with the
sham control group.
High BP variability correlates with higher cardio-
vascular event rates (13,14). In this trial, BP variability
was not signiﬁcantly different between groups at
6 months. Additionally, a reduction in early morning
BP surge or restoration of dipping status was not
affected by renal denervation (15,16).
Small reductions in ofﬁce-measured heart rate as
well as glycemic control were observed in previous
trials of renal denervation. In the current trial, 24-h
heart rate and glycemic control did not signiﬁcantly
change from baseline in either group. There are a
few possible reasons for this observation. First,
effective denervation may not have occurred in all
patients randomized to denervation because there
was no deﬁnitive way to assess denervation. A second
possibility, however, is that the drug doses affecting
heart rate, which also would adversely affect glucose
control, may have been maximized in both groups,
hence blunting the small previous effect seen on
heart reduction and glycemic control. Regardless of
the possible causes, an effect on heart rate was not
seen in this trial.
Several possible explanations exist for the discor-
dant ﬁndings between the prior renal denervation
data and the present results (5,8,9). Previous re-
nal denervation studies described the change in
ABPM from baseline without a control arm, and
thus treatment efﬁcacy was assumed but could not
be veriﬁed. This trial also observed signiﬁcant
ambulatory BP reductions from baseline to 6 months
following renal denervation, but the similar signiﬁ-
cant 24-h ambulatory BP drop in the sham control
group resulted in a lack of signiﬁcant difference
between the 24-h ambulatory BP reductions between
the 2 groups. It is intriguing that the nocturnal
SBP and DBP dropped signiﬁcantly from baseline,
but the BP reductions in the sham control group
were less and were not signiﬁcantly different from
baseline (Figure 2). The similar overall ambulatory BP
reduction seen in the sham control arm may be
partly attributed to participation in a trial that pro-
vided a high degree of patient support and oversight
that may have led to improved adherence with
medications and diet, an observation known as
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Compared with
a sham procedure, catheter-based renal artery sympathetic
denervation did not reduce BP either during daytime or nighttime
periods, as assessed by systematic ABPM.
COMPETENCY IN PATIENT CARE: Renal artery denervation
is an investigational procedure not currently approved for clinical
use in the United States, and it should not be recommended for
patients with resistant hypertension outside the context of
properly designed and regulated clinical trials.
TRANSLATIONALOUTLOOK:Additional studies are needed to
assess whether selection of hypertensive patients according to
different criteria, alternative methods, or more complete renal
artery sympathetic denervation could provide more effective BP
control.
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1077the Hawthorne effect (17,18). These data suggest that
the prior renal denervation studies overestimated
the treatment effect of the procedure.
The potential contribution of a placebo effect to
the BP reductions attributed to renal denervation in
prior studies cannot be ascertained (19,20). Our
analysis suggests that a placebo effect, perhaps
enhanced by the interventional procedure in the
control group, did affect BP change. Alternatively,
however, one could hypothesize that the placebo ef-
fect could have worsened BP in the intervention
group because the patient may have been concerned
that he or she received sham treatment. Both these
statements are speculative at best; however, this
observation has important implications for future
trial designs of medications and devices for hyper-
tension and other diseases.
STUDY LIMITATIONS. There are limitations in inter-
preting the data from this trial. There was no valida-
tion of medication adherence by assessing urine
levels for metabolites of antihypertensive drugs. It is
well documented that more than 50% of patients with
resistant hypertension are nonadherent with medi-
cations (21,22). In this trial, however, assessment of
patient diaries completed before treatment and
again before unblinding at 6 months fails to suggest a
difference in medication adherence between the
groups. Moreover, only 5.8% of subjects had medi-
cation changes during the 2 weeks before the second
screening visit. Although that may have affected
baseline BP, no signiﬁcant differences in ofﬁce BP
or ABPM were noted between groups at screening
visits. Medication adherence may have improved as a
result of the intervention, as suggested by changes in
ABPM at 6 months in the sham control group. This
ﬁnding further supports the concept of an objective
measure of medication adherence in patients en-
rolled in trials to treat drug-resistant hypertension.
Finally, there was no formal prospective assessment
of generator values of impedance, and this may
account for a variable response between centers.
The trial was not powered to detect small differ-
ences in ambulatory BP or any potential differences
in pre-speciﬁed subgroups. The trend for improved
nighttime BP control following renal denervation
that was not detected during the day suggests the
need for further research on the physiologic effects
of renal denervation. A relative lack of operator ex-
perience could have affected the outcomes in the
renal denervation group, although all procedures
were proctored. However, we found no evidence of
an operator learning curve when results of early
procedures were compared with later procedures.
The catheter generator system provides conﬁrmationof energy delivery, but no biomarker or easily
applied test is available to conﬁrm adequate dener-
vation at the time of the treatment. Finally, these
trial results are speciﬁc to the Symplicity catheter
and may not be generalizable to other renal dener-
vation systems.
CONCLUSIONS
The current trial conﬁrms the safety of renal dener-
vation with the Symplicity catheter; however, a sig-
niﬁcant BP-lowering effect on 24-h ambulatory BP
was not observed. Further clinical research using
rigorous trial design will be required to understand
whether renal denervation has any role in the treat-
ment of resistant hypertension.
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